Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 3

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 15
Chunk 3
---
1
     
    333-259853

    10.07(d)+
     
    2021 Plan Form of Restricted Stock Unit Award Grant Notice and Agreement
     
    99.4
     
    S-8
     
    September 28, 2021
     
    333-259853

    10.08+
     
    Executive Performance Incentive Bonus Plan, adopted September 2022
     
    10.5
     
    10-Q
     
    November 10, 2022
     
    001-12830

    COMMERCIAL AGREEMENTS

    10.09
     
    Commercial License and Option Agreement between Registrant and Wisconsin Alumni Research Foundation (“WARF Agreement”)
     
    10.1
     
    8-K
     
    January 9, 2008
     
    001-12830

    10.09(a)
     
    First Amendment to WARF Agreement dated March 11, 2009
     
    10.38
     
    10-K
     
    March 23, 2009
     
    001-12830

    10.10**
     
    Second Amended and Restated License Agreement dated June 15, 2017, between Cell Cure Neurosciences, Ltd. and Hadasit Medical Research Services and Development Ltd. (“Hadasit License”)
     
    10.1
     
    10-Q
     
    August 8, 2024
     
    001-12830

    10.10(a)
     
    Amendment to Hadasit License dated January 8, 2018
     
    10.38
     
    10-K
     
    March 15, 2018
     
    001-12830

    10.10(b)††
     
    Second Amendment to Hadasit License dated December 1, 2019
     
    10.4(b)
     
    10-K
     
    March 10, 2022
     
    001-12830

137

    10.10(c)††
     
    Side Letter Agreement dated December 17, 2021 between Hadasit Medical Research Services and Development Ltd., Cell Cure Neurosciences Ltd., Genentech,